The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

Share Price Information for Microsaic (MSYS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.00
Bid: 0.95
Ask: 1.05
Change: 0.00 (0.00%)
Spread: 0.10 (10.526%)
Open: 1.00
High: 1.00
Low: 1.00
Prev. Close: 1.00
MSYS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update and Directorate change

25 Sep 2023 07:00

RNS Number : 4428N
Microsaic Systems plc
25 September 2023
 

25 September 2023

Microsaic Systems plc

("Microsaic" or the "Company")

Update and Directorate change

 

 

The Company announced on 26 and 29 June 2023 that it was likely that the Company will need to raise further working capital in Q3 2023. The Company currently has cash in the bank of approximately £350k with no debt, and collectable trade debtors of circa £100k, and continues to meet its obligations as they fall due, providing a funding runway through to mid-November.

 

The Company is evaluating alternatives including discussions with several parties about strengthening the balance sheet and aims to conclude a fundraising within that period. The Company would then seek reinstatement of its shares to trading on AIM shortly afterwards, subject also to having published the FY22 report and accounts on a going concern basis, issued its interim results to 30 September 2023 and augmented the leadership team. Such fundraising is likely to be subject to shareholder approval to issue and allot new shares. An amount of approximately £1.5-2.0m would provide sufficient funds to remain a going concern, with additional funds to be targeted principally on the final testing and marketing of the Company's new innovative products, namely an acrylamide detector and ProteinID technology that it expects to bring to market in 2024.

 

Gerry Brandon, Executive Chairman, has resigned and will leave the Company and the Board with immediate effect, to enable him to devote more time to his other business commitments. Gerry joined the Company in January 2021 and has been instrumental in the transformation of the Company to be a commercially focused service provider as well as a mass spectrometry manufacturing business.

 

The Company is pleased to announce the appointment of Bob Moore, who joined the Company as a Non-Executive Director in March 2022, as Executive Chairman.

 

In addition to the above management changes, the Company intends to progress with the recruitment of a new CEO to ensure that the Company has the full set of skills necessary to take the business forward and return to compliance with the appropriate corporate governance standards. At that time it is expected that Bob Moore would revert to a non-executive role.

 

Bob Moore commented: "The Company and Board are grateful for the contribution that Gerry has made to the development of the Company since early 2021, particularly during the difficult period during and following the Covid pandemic. We wish him well in his future endeavours."

 

Further announcements will be made as appropriate.

Enquiries:

Microsaic Systems plc

Bob Moore Chairman and interim Chief Executive

+44 (0)1483 751 577

Singer Capital Markets (Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell (Investment Banking)

 

 

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

 

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information as stipulated under the UK version of the market abuse regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

About Microsaic (www.microsaic.com)

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

 

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing, and point-of-need applications. Microsaic is an innovative company. Most recently the Company has developed an Acrylamide detector for use in the food industry and a ProteinID detector for the bio-pharmacy industry that will greatly reduce the wastage cost by early detection of expensive product failure throughout the biopharmaceutical drug manufacturing process. Both products are at the final stage of development and are expected to be released to the market in 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDCLBDDGXS
Date   Source Headline
15th Mar 20227:00 amRNSBoard Appointment and Strategic Update
8th Mar 20224:35 pmRNSPrice Monitoring Extension
7th Mar 20222:05 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20221:31 pmRNSHolding(s) in Company
17th Feb 20222:45 pmRNSHolding(s) in Company
16th Feb 202211:06 amRNSSecond Price Monitoring Extn
16th Feb 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSDirector Dealing, Issue of Equity and TVR
28th Jan 20227:00 amRNSResignation of Chief Executive Officer
12th Jan 20224:43 pmRNSHolding(s) in Company
10th Jan 20223:30 pmRNSInvestor Presentation
10th Jan 20227:00 amRNSTrading Update
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSFurther order from DeepVerge
12th Nov 20217:00 amRNSNew compact screening platform
5th Nov 202110:12 amRNSHolding(s) in Company
27th Oct 20217:00 amRNSLaunch of technology for scaling drug manufacture
22nd Oct 20217:00 amRNSBoard Change
21st Oct 20217:00 amRNSUpdate on DeepVerge Collaboration
28th Sep 20214:30 pmRNSHolding(s) in Company
27th Sep 20217:00 amRNSInterim Results
24th Sep 20217:00 amRNSSigning of agreement to support China operations
22nd Sep 202111:06 amRNSNotice of Results and Investor Presentation
27th Aug 20214:40 pmRNSSecond Price Monitoring Extn
27th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSDeepVerge Collaboration for Water & Soil Analysis
9th Aug 20217:00 amRNSHeads of Terms signed with manufacturer in China
6th Jul 202111:55 amRNSInvestor Presentation
6th Jul 20217:00 amRNSTrading update for H1 2021
5th Jul 20219:50 amRNSHolding(s) in Company
2nd Jul 20217:00 amRNSDevelopment of real-time monitoring solution
17th Jun 202110:54 amRNSResult of Annual General Meeting
4th Jun 20217:00 amRNSPre-Annual General Meeting Q&A
25th May 20217:00 amRNSDevelopment of PFAS detection platform
20th May 20217:00 amRNSPosting of Annual Report and Notice of AGM
4th May 20219:00 amRNSPrice Monitoring Extension
4th May 20217:01 amRNSHeads of Terms signed for Chinese market
4th May 20217:00 amRNSFinal Results
28th Apr 20217:00 amRNSNotice of Results and Investor Presentation
31st Mar 20214:41 pmRNSSecond Price Monitoring Extn
31st Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20217:00 amRNSFramework Services Agreement Update
9th Mar 20212:52 pmRNSHolding(s) in Company
9th Mar 20212:06 pmRNSSecond Price Monitoring Extn
9th Mar 20212:01 pmRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSHolding(s) in Company
3rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
3rd Mar 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.